Deschatelets Pascal 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 21, 2026
Research Summary
AI-generated summary of this filing
Apellis (APLS) CSO Pascal Deschatelets Sells 909 Shares
What Happened
- Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals (APLS), sold 909 shares on January 20, 2026 at $19.79 per share, generating proceeds of $17,992. The filing indicates the sale was to cover tax withholding on Restricted Stock Units released January 16, 2026.
Key Details
- Transaction date and price: 2026-01-20, 909 shares at $19.79 each.
- Total proceeds: $17,992.
- Shares owned after transaction: Not specified in the provided filing.
- Transaction code: S (sale); footnote F1: sale made to cover tax withholding on RSUs released 1/16/2026.
- Filing date: 2026-01-21 (appears timely based on the reported transaction date).
Context
- Sales to cover tax withholding on RSU vesting are routine and typically administrative (not a direct signal of confidence or lack thereof in the company). This was not an option exercise or a purchase; it was a disposal to satisfy taxes.
Insider Transaction Report
Form 4
Deschatelets Pascal
Chief Scientific Officer
Transactions
- Sale
Common Stock
[F1]2026-01-20$19.79/sh−909$17,992→ 1,157,310 total
Footnotes (1)
- [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 16, 2026.
Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets|2026-01-21